Literature DB >> 12654696

Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

Dean W Selleseth1, Christine L Talarico, Teresa Miller, Michael W Lutz, Karen K Biron, Robert J Harvey.   

Abstract

Inhibition of human cytomegalovirus (HCMV) by 1263W94 was additive dosewise in combination with ganciclovir, acyclovir, and foscarnet. None of the commonly used anti-human immunodeficiency virus agents antagonized the inhibition of HCMV by 1263W94. The data were analyzed by a modified isobologram procedure that measures the strength and statistical significance of drug interactions.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12654696      PMCID： PMC152503          DOI： 10.1128/AAC.47.4.1468-1471.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Allosteric proteins and cellular control systems.

Authors:  J MONOD; J P CHANGEUX; F JACOB
Journal:  J Mol Biol       Date:  1963-04       Impact factor: 5.469

2.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.

Authors:  G B ELION; S SINGER; G H HITCHINGS
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

Review 3.  A three-dimensional model to analyze drug-drug interactions.

Authors:  M N Prichard; C Shipman
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

4.  Evaluation of synergism or antagonism for the combined action of antiviral agents.

Authors:  J Sühnel
Journal:  Antiviral Res       Date:  1990-01       Impact factor: 5.970

5.  The expected effect of a combination of agents: the general solution.

Authors:  M C Berenbaum
Journal:  J Theor Biol       Date:  1985-06-07       Impact factor: 2.691

6.  Synergism in the folate pathway.

Authors:  R J Harvey
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

7.  Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.

Authors:  W R Greco; H S Park; Y M Rustum
Journal:  Cancer Res       Date:  1990-09-01       Impact factor: 12.701

8.  Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product.

Authors:  M R Underwood; R J Harvey; S C Stanat; M L Hemphill; T Miller; J C Drach; L B Townsend; K K Biron
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Authors:  Karen K Biron; Robert J Harvey; Stanley C Chamberlain; Steven S Good; Albert A Smith; Michelle G Davis; Christine L Talarico; Wayne H Miller; Robert Ferris; Ronna E Dornsife; Sylvia C Stanat; John C Drach; Leroy B Townsend; George W Koszalka
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent.

Authors:  J C Martin; C A Dvorak; D F Smee; T R Matthews; J P Verheyden
Journal:  J Med Chem       Date:  1983-05       Impact factor: 7.446
  10 in total
  14 in total

1.  Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

Authors:  Tomokazu Yoshinaga; Masanori Kobayashi; Takahiro Seki; Shigeru Miki; Chiaki Wakasa-Morimoto; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

3.  Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.

Authors:  Richard J Hazen; Robert J Harvey; Marty H St Clair; Robert G Ferris; George A Freeman; Jeffrey H Tidwell; Lee T Schaller; Jill R Cowan; Steven A Short; Karen R Romines; Joseph H Chan; Lawrence R Boone
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus.

Authors:  Sunwen Chou; Gail I Marousek
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

5.  The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.

Authors:  Rima Kulkarni; Rebecca Hluhanich; Damian M McColl; Michael D Miller; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

6.  The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.

Authors:  Edward P Garvey; Brian A Johns; Margaret J Gartland; Scott A Foster; Wayne H Miller; Robert G Ferris; Richard J Hazen; Mark R Underwood; Eric E Boros; James B Thompson; Jason G Weatherhead; Cecilia S Koble; Scott H Allen; Lee T Schaller; Ronald G Sherrill; Tomokazu Yoshinaga; Masanori Kobayashi; Chiaki Wakasa-Morimoto; Shigeru Miki; Koichiro Nakahara; Takeshi Noshi; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

7.  In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.

Authors:  Richard Hazen; Robert Harvey; Robert Ferris; Charles Craig; Phillip Yates; Philip Griffin; John Miller; Istvan Kaldor; John Ray; Vincente Samano; Eric Furfine; Andrew Spaltenstein; Michael Hale; Roger Tung; Marty St Clair; Mary Hanlon; Lawrence Boone
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

8.  Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus.

Authors:  Sunwen Chou; Ronald J Ercolani; Katayoun Derakhchan
Journal:  Antiviral Res       Date:  2018-07-21       Impact factor: 5.970

Review 9.  Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection.

Authors:  Scott H James; David W Kimberlin; Richard J Whitley
Journal:  Antiviral Res       Date:  2009-05-04       Impact factor: 5.970

10.  The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Authors:  Joy Y Feng; John K Ly; Florence Myrick; Derrick Goodman; Kirsten L White; Evguenia S Svarovskaia; Katyna Borroto-Esoda; Michael D Miller
Journal:  Retrovirology       Date:  2009-05-13       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.